Truncation of C-mip (Tc-mip), a New Proximal Signaling Protein, Induces c-maf Th2 Transcription Factor and Cytoskeleton Reorganization

Grimbert, Philippe; Valančiūtė, Asta; Audard, Vincent; Pawlak, André; gouvelo, Sabine Le; Lang, Philippe; Niaudet, Patrick; Bensman, A; Guellaën, Georges; Sahali, Dil

doi:10.1084/jem.20030566

Cited by 74 publications

(68 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, rituximab could induce a proteinuria decrease through mechanisms independent of B cell depletion. Thus, recent studies have uncovered unexpected similarities between lymphocytes and podocytes (27), and some proteins shared by lymphocytes and podocytes are upregulated in patients with nephrotic syndrome (28).…”

Section: Discussionmentioning

confidence: 99%

Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis

Fernández‐Fresnedo

Segarra

González

et al. 2009

Clinical Journal of the American Society of Nephrology

107

View full text Add to dashboard Cite

Background and objectives: Isolated case reports have shown a beneficial effect of rituximab on pediatric patients with primary FSGS, but there is no information about rituximab treatment of FSGS in adults.Design, setting, participants, & measurements: All patients who had biopsy-proven FSGS and were treated with rituximab in Spain were identified, independent of their positive or negative response, among the nephrology departments that belong to the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Their characteristics and outcome after rituximab treatment were studied.Results: Eight patients were identified. Rituximab failed to improve nephrotic syndrome in five of eight patients, who continued to show massive proteinuria and exhibited a rapidly deteriorating renal function in two cases. Among the remaining three patients, two of them showed an improvement of renal function and a remarkable proteinuria reduction and one experienced a beneficial but transitory effect after rituximab. There were no differences in clinical or laboratory characteristics or in the CD20 B lymphocyte count after rituximab between these three patients and the five who had a negative response. The only difference was in the regimen of rituximab administration: Whereas the five patients with a negative response received only four weekly consecutive infusions of 375 mg/m 2 , the three remaining patients received additional doses of rituximab.Conclusions: Only a minority (three of eight) of patients in our series of adult patients with FSGS showed a positive influence of rituximab. More studies are necessary to characterize further the optimal dosages and the mechanisms of action of rituximab in FSGS.

show abstract

Section: Discussionmentioning

confidence: 99%

Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis

Fernández‐Fresnedo

Segarra

González

et al. 2009

Clinical Journal of the American Society of Nephrology

107

View full text Add to dashboard Cite

show abstract

“…The pathogenesis of minimalchange disease seems to involve a putative circulating factor secreted by T lymphocytes, leading to cytoskeleton disorganization and heavy proteinuria (38). A new gene named for c-maf-inducing protein (c-mip) has recently been isolated (39). During primary nephrotic syndrome, c-mip increases in the podocytes and turns off podocyte signaling by preventing the interaction of nephrin with the tyrosine kinase Fyn, thereby decreasing nephrin phosphorylation.…”

Section: Hematologic Malignancy-induced Paraneoplastic Glomerulopathimentioning

confidence: 99%

Onco-Nephrology

Cambier

Ronco

2012

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryGlomerular diseases occurring in the course of malignancies remain rare. Diverse glomerular lesions can be observed in a variety of neoplasms and involve different pathophysiologic links between the glomerulopathy and the cancer. The pathophysiology of solid tumor-associated glomerulopathies remains obscure, whereas in hematologic malignancy-induced paraneoplastic glomerulopathies, a molecular link can usually be demonstrated. The aim of this review is to provide an update on glomerular diseases associated with carcinoma and hematologic malignancies, covering epidemiology, pathophysiology, clinical presentation, and therapy. Special emphasis will be placed on the potential usefulness of novel biomarkers, such as antiphospholipase A2 receptor antibodies, for the diagnosis of membranous nephropathy, and on new associations and recent entities, including (proliferative) GN with nonorganized monoclonal immunoglobulin deposits and myeloproliferative neoplasmrelated glomerulopathy.

show abstract

“…Pour tenter de comprendre ces mécanismes et identifier les gènes potentiellement en cause, nous avons réalisé un clonage soustractif et différentiel à partir de lymphocytes de patients atteints de syndrome néphrotique, prélevés en phase de poussée et en rémission. Ce travail a permis l'identification d'un nouveau gène appelé c-mip parce qu'il peut induire in vitro le facteur de transcription c-maf [13,14]. Le gène c-mip s'étend sur 268 kpb et est localisé sur le chromosome 16 en position q23.…”

Section: Découverte Du Gène C-mipunclassified